Oncology drug discovery is, by definition, a target-rich enterprise. High-throughput screening (HTS) laboratories have supported a wide array of molecularly targeted and chemical genomic approaches for anticancer lead generation, and the number of hits emerging from such campaigns has increased dramatically. Although automation of HTS processes has eliminated primary screening as a bottleneck, the demands on secondary screening in appropriate cell-based assays have increased concomitantly with the numbers of hits delivered to therapeutic area laboratories. The authors describe herein the implementation of a novel platform using off-the-shelf solutions that have allowed them to efficiently characterize hundreds of HTS hits using a palette of Western blot-based pharmacodynamic assays. The platform employs a combination of a flatbed bufferless SDS-PAGE system, a dry ultra-rapid electroblotting apparatus, and a highly sensitive and quantitative infrared imaging system. Cumulatively, this platform has significantly reduced the cycle time for HTS hit evaluation. In addition, the routine use of this platform has resulted in higher quality data that have allowed the development of structure-activity databases that have tangibly improved lead optimization. The authors describe in detail the application of this platform, designated the Accelerated Pharmaco-Dynamic Profiler (APDP), to the annotation of inhibitors of 2 attractive oncology targets, BRAF kinase and Hsp90. (Journal of Biomolecular  FIG . 2. Dose-dependent pharmacodynamic effects of BRAF and Hsp90 inhibition as determined by the Accelerated Pharmaco-Dynamic Profiler (APDP). (A) A375 cells were left untreated or treated with various concentrations of BRAF kinase inhibitors as indicated for 1 h. The levels of phosphorylated ERK (phospho-ERK or P-ERK) and total ERK were assessed using the APDP as described in Materials and Methods. The intensity of each band was quantitated using the infrared imaging system, and the IC 50 s of phospho-ERK were determined. Total ERK was also quantitated and served as a loading control. Sorafenib was used as a reference compound. (B) SKBR3 cells were left untreated or treated with various concentrations of Hsp90 inhibitors as indicated for 8 h. The levels of HER2 and β-actin were assessed by APDP as described in Materials and Methods. The intensity of each band was quantitated using infrared imaging, and the IC 50 s of HER2 degradation were determined. β-Actin was used as loading control, and known Hsp90 inhibitors 17-AAG and radicicol were used as reference compounds.
INTRODUCTION
H UMAN CANCER REPRESENTS well over 200 distinct diseases, and a wide variety of genetic abnormalities have been documented in a number of different cancer types. One such example is the discovery of a mutation in 1 residue (V600E) in the BRAF kinase protein that results in its constitutive activation and aberrant signaling of the BRAF/MEK/ERK signaling pathway. This activating mutation contributes to the initiation and maintenance of a transformed oncogenic phenotype, characterized by unchecked cellular proliferation. This BRAF mutation has been found in 60% to 70% of human melanomas, 36% to 69% of papillary thyroid carcinomas, and 5% to 10% of human colon cancers and a smaller percentage of other cancers. [1] [2] [3] Another emerging target in the oncology arena is heat shock protein 90 (Hsp90), a molecular chaperone protein that is critical in ensuring the appropriate folding, stability, and function of other proteins in the cellular environment. Interestingly, Hsp90 is essential for the stability of a broad spectrum of client proteins that are involved in oncogenic pathways, such as c-Met, Bcr-Abl, HER2, c-Raf-1, and CDK4. [4] [5] [6] [7] [8] [9] Inhibition of Hsp90 leads to depletion of these oncogenic clients through the ubiquitin-mediated proteasome degradation pathway. In addition, Hsp90 inhibitors may be able to selectively kill cancer cells as compared to normal cells, creating a unique potential therapeutic window for these compounds. 4 For both of these targets, we developed microplate-based primary biochemical assays suitable for high-throughput screening (HTS) and interrogated compounds generated from ArQule's combinatorial chemistry efforts, yielding Lipinski-compliant drug-like molecules, a proprietary platform that has been described in detail elsewhere. 10, 11 The results of these screening campaigns led to a need to evaluate several hundreds of compounds in cell-based assays for each discovery program. For compounds inhibiting BRAF kinase activity, for example, it was critical to assess the phosphorylation of downstream targets MEK and ERK, as well as the family of cyclin D proteins. For compounds that were shown to compete for binding to Hsp90 with a known inhibitor of Hsp90, geldanamycin, high-capacity Western blotting 12 analysis was needed to assess the degradation of a wide array of Hsp90 client proteins such as HER2, c-Raf, AKT, phospho-AKT, and cyclin-dependent kinase 4 (CDK4). These analyses, furthermore, needed to be performed against a wide array of cancer cell lines, and the inhibitors required interrogation with respect to dose dependency, time dependency, and durability of response. Taken together, these assays exacerbated the bottleneck of these cell-based compound evaluations and necessitated the implementation of an efficient platform that could rapidly generate thousands of data points on a continuous basis. To fulfill these profiling needs and to address this bottleneck, we first employed the E-PAGE™ SDS-PAGE horizontal flatbed bufferless system (Invitrogen, Inc., Carlsbad, CA) that allows for 48 samples per gel to be loaded with 12-tip pipettors, in contrast to standard SDS-PAGE systems that require loading 1 sample at a time. Second, we opted to improve the efficiency of electrotransfer of the protein in the gels to nitrocellulose membranes with the use of the iBlot™ transfer system (Invitrogen) that quantitatively transfers all proteins in 7 min, in contrast to transfer times of 1 to 4 h with previously available technologies. Finally, the adoption of the LI-COR™ infrared imaging system allowed for superior sensitivity, linearity, and reproducible quantitation as compared to formerly employed X-ray film-based technologies for Western blotting. Taken together, the weaving of these 3 technologies into a routine standardized platform increased our throughput approximately 10-fold, and this user-friendly platform, designated the Accelerated Pharmaco-Dynamic Profiler (APDP), substantially reduced the cycle time of lead nomination without the utilization of additional personnel.
MATERIALS AND METHODS
The development and optimization of microplate-based primary screens for BRAF kinase and Hsp90 are described elsewhere. Briefly, the BRAF assay consisted of measuring the degree of phosphorylation of its downstream target, MEK. The Hsp90 assay tested the ability of compounds to compete with biotinylated geldanamycin, a known inhibitor of Hsp90 that binds to the amino terminal adenosine triphosphate (ATP) binding region. 13 For both BRAF and Hsp90 primary screens, all compounds exhibiting dose-dependent inhibition exhibiting IC 50 s of 2 micromolar or less were advanced to the secondary assays described below. Hsp90 inhibitors radicicol 14 (Sigma, St. Louis, MO) and geldanamycin (Calbiochem, San Diego, CA) were obtained from commercial sources. A375 and SKBR3 cells were obtained from the ATCC and maintained at 37 °C, 5% CO 2 in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, penicillin/streptomycin, and fungizone (Invitrogen, Carlsbad, CA). Test compounds were dissolved in 100% DMSO and subsequently diluted in DMEM to a final DMSO concentration not exceeding 0.1%. Cells were seeded in 6-well tissue culture plates at 5 to 8 × 10 5 per well and cultured at 37 °C for 24 h. Cells were incubated with compounds for various times before being lysed in E-PAGE™ loading buffer (Invitrogen). Cell lysates were sonicated and subjected to electrophoresis on 8% acrylamide E-PAGE™ gels (Invitrogen) and quantitatively transferred to polyvinylidene difluoride membranes using the iBlot™ (Invitrogen) transfer system in 7 min. After incubations with primary and secondary antibodies, the immunostained proteins were detected and quantitated by an Odyssey™ infrared imager (LI-COR Biosciences, Lincoln, NE). Analysis was performed by nonlinear regression to generate a dose-response curve. For the BRAF pharmacodynamic assays, the primary antibodies used were anti-MEK (Nventa, Ann Arbor, MI), anti-ERK (BD Biosciences, San Jose, CA), anti-phospho-ERK, and anti-phospho-MEK (Cell Signaling Technology, Danvers, MA). For the Hsp90 pharmacodynamic assays, the primary antibodies used were anti-Raf-1 (BD Biosciences), anti-HER2, anti-AKT, anti-phospho-AKT, anti-phospho-ERK (Cell Signaling Technology), β-actin (Sigma), and anti-CDK4 (Santa Cruz Biotechnology, Santa Cruz, CA). The secondary antibodies used were IRDye™ 800 antirabbit IgG, IRDye™ 800 antimouse IgG (Rockland, Gilbertsville, PA), Alexa Fluor 680 antimouse IgG, and Alexa Fluro 680 antirabbit IgG (Invitrogen). The calculated IC 50 values obtained were defined at the concentration of the test compound that resulted in a 50% decrease in phospho-MEK and phospho-ERK levels. The methodology for quantitating the decrease in Hsp90 client proteins in response to treatment by Hsp90 inhibitors was nearly identical to that described above.
RESULTS

Sensitivity and linearity of APDP
Prior to implementing this platform, our laboratory relied on vertical SDS-PAGE slab gels, typically run with 12 lanes per gel, semidry electroblotting using polyvinylidene difluoride (PVDF) membranes, and, finally, Enhanced Chemiluminescence (ECL™) using X-ray film with standard densitometry for quantitation. Beyond the obvious need to increase throughput, there was a concern that X-ray film may not be linear with respect to concentration of protein versus signal intensity. Also, particularly for Hsp90 pharmacodynamic (PD) assays, it was imperative that the sensitivity of detection be maximal because we were tracking the disappearance of Hsp90 client proteins in lysates of cells. Our initial experience comparing ECL and the infrared Western blotting was entirely consistent with a technical bulletin 15 from the vendor (LI-COR Biosciences) documenting that X-ray film with ECL is not as sensitive as the infrared detection system and that the infrared imaging technology exhibits superior linearity. We therefore sought to determine the precise lower limit of detection for the infrared Western blot technology using MEK protein. Various amounts of purified MEK protein were subjected to SDS-PAGE, electrotransferred onto nitrocellulose membranes, and infrared imaging performed as described in Materials and Methods. The results in Figure 1 show that the absolute lower limit of detection determined for MEK protein in this experiment was 0.5 nanograms per lane.
Reproducibility of quantitation by APDP
Using the data depicted in Figure 1A ,B, we assessed both the intragel coefficient of variability (%CV) and the intergel %CVs. The experiment consisted simply of running the same sample of MEK protein at 9 different concentrations in triplicate on 4 different gels. The Western blots are shown in Figure 1 . The intragel %CV was determined to be 2% and 8% at 125 ng and 63 ng, respectively. The intergel %CV was determined to be 7% and 11% at 125 ng and 63 ng, respectively. This low degree of variability is potentially ascribable to the low operator error in loading the horizontal gels, the virtual absence of "smile effects" on the gels, and the quantitatively complete transfer achieved by the electroblotting apparatus, as evidenced by Coomassie blue staining of SDS-PAGE gels after transfer (data not shown). Most certainly, the short transfer time of the electroblotting (7 min) ensured that diffusion of proteins within the acrylamide gel was not a significant issue, as may be the case with other electroblotting methods that require longer transfer times.
Dose dependency of pharmacodynamic effects
To evaluate the ability of this platform to assess the dose dependency of compounds inhibiting the BRAF pathway and the biological effects of Hsp90 inhibition, studies were conducted over a broad range of concentrations with both known inhibitors and ArQule compounds that had been identified in primary screens. For the BRAF pathway, the antibodies against phospho-ERK (P-ERK) yielded sharper and more reliable bands on the Western blots than phospho-MEK, a result echoed by the numerous labs using phospho-ERK as a downstream PD marker of the pathway. 16 Figure 2A shows the dose dependency of phospho-ERK inhibition of 2 ArQule BRAF inhibitors compared with the recently launched kinase inhibitor Sorafenib (Bayer, West Haven, CT) as a reference compound in A375 cells. Our result for Sorafenib is consistent with those of Panka et al., 17 who showed Sorafenib exhibiting an IC 50 in inhibiting ERK phosphorylation at 10 to 20 µM, albeit at 4 h versus the 1-h exposure time in our experiment. This analysis has allowed us to rank compounds for further advancement with quantitative data of high quality, as evidenced by the accompanying graphs employed to determine the IC 50 s of these compounds. For Hsp90 inhibitors, we assessed the protein level of HER2 in SKBR3 with respect to their accelerated degradation following Hsp90 inhibition. Figure 2B shows a study in which we assessed 2 ArQule Hsp90 inhibitors as well as 2 known Hsp90 inhibitors, radicicol and geldanamycin, for dosedependent degradation of the oncoprotein HER2. The potencies determined for these 2 reference compounds were well within the range found by others in accelerating the degradation of this oncoprotein. 4, 9, 18 Once again, using this highly quantitative APDP platform, we were able to rapidly triage in-house synthesized Hsp90 inhibitors identified in the primary screen for their ability to inhibit their intended target in a relevant cellular context.
Pharmacodynamic effects at various time points
To assess the utility of the APDP platform to evaluate PD effects of test compounds at various time points, we conducted a number of studies, of which 2 representative experiments are shown below (Fig. 3) . For the BRAF pathway, we exposed A375 cells for various times to BRAF kinase inhibitors and interrogated the phosphorylation status of ERK using the APDP platform. As shown in Figure 3A , in this cancer cell line, the maximum inhibitory effect on ERK phosphorylation was observed after 1 h to either Sorafenib or the ArQule BRAF inhibitors, with the latter compounds exerting a more pronounced maximal effect than Sorafenib at the single concentration of 600 nM employed in this experiment. Figure 3B shows the results of an analogous experiment conducted in MDA-MB-231 cells with various Hsp90 inhibitors, using the diminution of phospho-ERK as a PD marker of Hsp90 inhibition. The result of this experiment suggests that the maximum PD effect of Hsp90 inhibition occurs sometime between 8 and 24 h, an observation that is consistent with published in vivo PD data. 19
Use of APDP for durability studies
Having prioritized BRAF kinase inhibitors by potency, we next employed APDP to evaluate the durability of response by deliberately removing the compounds from the A375 melanoma cells after 1 h and harvesting the cells at various time points. In this fashion, compounds can be identified that may exhibit a superior PD profile in vivo, either by virtue of a slow off-rate from the kinase or potential accumulation in tumor cells. Figure 4 shows the results of such an experiment. Although the degree of ERK phosphorylation rebounds rather quickly with Sorafenib and at least 1 of the ArQule BRAF inhibitors, other inhibitors show a reasonably sustained inhibition of ERK phosphorylation for up to 8 h.
Application of APDP to in vitro biomarker profiling
To assess the biological effects of Hsp90 inhibition in different cell types, we employed APDP to examine a number of Hsp90 client proteins in several cell lines that are derived from different tissues and possess different genetic backgrounds. We The levels of phospho-ERK were assessed using APDP. The intensity of each band was quantitated using the infrared imaging system, and the levels of phospho-ERK inhibition were determined and plotted. Total ERK protein was also quantitated and served as loading control. The reference BRAF inhibitor Sorafenib was used at a concentration of 10 µM in this assay. (B) SKBR3 cells were left untreated ("C") or treated with various Hsp90 inhibitors at a concentration of 1 µM for the indicated times. The levels of phospho-ERK were assessed using the APDP. The intensity of each band was quantitated by infrared imaging, and the extent of P-ERK inhibition was determined and plotted. β-Actin served as a loading control, and 17-AAG was used as a reference compound.
FIG . 4.
Assessment of pharmacodynamic durability using the Accelerated Pharmaco-Dynamic Profiler (APDP). A375 cells were left untreated ("C") or treated with BRAF inhibitors at a concentration of 600 nanomolar for 1 h. The compounds were then removed and the cells allowed to recover for the indicated time periods. The levels of phospho-ERK were assessed using APDP. The intensity of each band was quantitated using the infrared imaging system, and the levels of phospho-ERK inhibition were determined and plotted. Total ERK protein was also quantitated and served as loading control. The reference BRAF inhibitor Sorafenib was used at a concentration of 10 µM in this assay.
FIG . 5.
Using the Accelerated Pharmaco-Dynamic Profiler (APDP) to develop pharmacodynamic signatures for multiple human cancer cell lines. Cells were left untreated ("C") or treated with various concentrations of an ArQule proprietary Hsp90 inhibitor (ARQ-HSP90-1) as indicated for 8 h. The levels of the indicated proteins were quantitated by APDP immunoblotting using the requisite antibodies as described in Materials and Methods, with β-actin serving as a loading control. The intensity of each band was quantitated using infrared imaging, and the IC 50 s for each protein's degradation were determined as indicated in the accompanying table. ND indicates that an IC 50 was not determined for the indicated client protein.
conducted this study over a broad range of concentrations with 1 of the proprietary ArQule Hsp90 inhibitors. Interestingly, but not unexpectedly, each cell line shows a distinct pharmacodynamic signature (Fig. 5) . To cite 1 example, the receptor tyrosine kinase HER2 was only detected in BT474 and N87 cells, and in these cell lines, the immunodetectable levels of HER2 decreased in a dose-dependent fashion in response to Hsp90 inhibition ( Fig. 5) . Taken together, these data demonstrate that the APDP can readily be employed in vitro to identify pathophysiologically relevant proteins for subsequent in vivo and clinical biomarker studies. Table 1 shows a comparison of the methodology previously employed in our laboratory and the APDP that has been actively used in our laboratory for over a year. As one can see, this analysis favors APDP in every parameter evaluated. Although we have not performed a detailed comparison of cost per sample for both technologies, certainly the 10-fold increase in throughput and consequent productivity greatly outweighs any potential differential in either capital investment or consumable costs between the 2 approaches.
Overall impact on productivity
DISCUSSION
A common denominator of scientific innovation is often the melding of existing technologies in a novel fashion, sequence, or combination. We have employed this guiding principle in the implementation of a streamlined system using off-the-shelf commercially available equipment and reagents to biologically profile our proprietary hits, leads, and anticancer drug development candidates. Although there have been a number of application reports using the Odyssey infrared imager, [20] [21] [22] to our knowledge, this is the first report that has combined the bufferless E-PAGE™ gel system and iBlot™ electroblotting system from Invitrogen with the infrared imaging system from LI-COR and the first to provide a detailed critical evaluation of the quantitative parameters and productivity increases enabled by this suite of technologies. We have shown that the reproducibility of the combined platform is excellent, with coefficients of variability rivaling biochemical assays. Real-world applications of APDP were shown with BRAF kinase and Hsp90 inhibitors discovered in our laboratories with known reference compounds as standards. The quality of the quantitation provided by APDP was shown in studies in which dose and time dependency were shown for both targets. The utility of APDP for informative cell-based profiling assays was documented by assessing the durability of BRAF pathway suppression in response to BRAF kinase inhibition in human melanoma cancer cells harboring an activating mutation of BRAF. Based on these compelling in vitro data, the APDP will now be our platform of choice for quantitative PD assessment for in vivo pharmacokinetic/pharmacodynamic/efficacy studies using human cancer cell lines in xenograft models. In summary, we have described the implementation of a novel platform for pharmacodynamic profiling of compounds that has increased the throughput of such analyses by at least a factor of 10 but also, perhaps more important, provided exquisitely quantitative data that have allowed informed decisions about compound advancement in the context of a variety of molecularly targeted oncology campaigns. 
